196 related articles for article (PubMed ID: 19460840)
21. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
22. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.
van Wezel EM; Stutterheim J; Vree F; Zappeij-Kannegieter L; Decarolis B; Hero B; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; Voermans C; van Noesel MM; Caron HN; van der Schoot CE; Tytgat GA;
Pediatr Blood Cancer; 2015 Aug; 62(8):1368-73. PubMed ID: 25939774
[TBL] [Abstract][Full Text] [Related]
24. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract][Full Text] [Related]
25. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
27. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
Cheung IY; Feng Y; Gerald W; Cheung NK
Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
[TBL] [Abstract][Full Text] [Related]
28. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
29. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
[TBL] [Abstract][Full Text] [Related]
30. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
Fan H; Xing T; Hong H; Duan C; Zhao W; Zhao Q; Wang X; Huang C; Zhu S; Jin M; Su Y; Gao C; Ma X
Pediatr Hematol Oncol; 2022 May; 39(4):343-356. PubMed ID: 34752187
[TBL] [Abstract][Full Text] [Related]
31. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
32. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
Kuroda T; Saeki M; Nakano M; Mizutani S
J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
[TBL] [Abstract][Full Text] [Related]
33. RT-qPCR for
Grèze V; Kanold J; Chambon F; Halle P; Gremeau AS; Rives N; Rouel N; Pereira B; Tchirkov A; Brugnon F
Oncol Lett; 2017 Jul; 14(1):860-866. PubMed ID: 28693243
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
35. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
36. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
[TBL] [Abstract][Full Text] [Related]
38. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
[TBL] [Abstract][Full Text] [Related]
39. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
